Difference between revisions of "Melphalan (Alkeran)"
(updated content) |
m (→Also known as) |
||
| Line 21: | Line 21: | ||
==Also known as== | ==Also known as== | ||
| − | Alkerana | + | Precise Name: Melphalan hydrochloride (RXCUI 235857) |
| + | |||
| + | {| border="1" style="text-align:center;" | ||
| + | !colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
| + | |- | ||
| + | |Alkerana | ||
| + | |L-PAM | ||
| + | |L-Sacrolysin | ||
| + | |L-Sarcolysin | ||
| + | |Levofolan | ||
| + | |Melfalan | ||
| + | |} | ||
==References== | ==References== | ||
Revision as of 17:56, 23 October 2013
General information
Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bone cancer
- Hodgkin lymphoma
- Light-chain (AL) amyloidosis
- Multiple myeloma
- Transplant conditioning regimens
Patient drug information
- Melphalan (Alkeran) patient drug information (Chemocare)[3]
- Melphalan (Alkeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1/17/1964: Initial FDA approval[5]
Also known as
Precise Name: Melphalan hydrochloride (RXCUI 235857)
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkerana | L-PAM | L-Sacrolysin | L-Sarcolysin | Levofolan | Melfalan | ||